On September 19, 2013, Agilent Technologies Inc. (NYSE: A) announced that its Board of Directors had approved plans to spin off its electronic measurement (EM) business into a separate publicly traded company, Keysight Technologies, through a tax-free distribution of shares to A shareholders to be completed by the end of 2014, while retaining its life sciences and diagnostics business. Keysight has applied to list on the NASDAQ with the ticker “KEYS”. Agilent was originally a division of Hewlett-Packard Company (NYSE: HPQ), which became a public company in 1999. Both entities will seek to maintain leverage ratios below 2x. The parent, which will retain the Agilent name, intends to pay an annual dividend of approximately $130 million per year, implying a yield at least equivalent to the current 0.9%. Bill Sullivan will remain CEO of the parent, based in Santa Clara, CA (approximately 11,500 employees), while the current president, Ron Nersesian, will assume duties of CEO for Keysight, based in Santa Rosa, CA (9,500 employees).
Agilent and Keysight have similar business models as test and diagnostics companies, but serve vastly different end markets. Post-spin Agilent generates about $3.9 billion in annual revenue (about 41% recurring), and Keysight about $2.9 billion. The companies generate similar operating margins (19%-20%) although, importantly, Keysight is growing at a slower rate (3% annually versus 6% for Agilent). Keysight is exclusively focused on electronic measurement, and provides products used to test communications networks, mobile handsets, and other electronic devices – primarily serving the communications, aerospace and defense, and semiconductor industries. Agilent will be exclusively focused on test, diagnostics, and chemical analysis tools for the life sciences industries – serving the pharmaceutical, biotech, chemicals, food, and energy markets.
The transaction makes sense given the disparate nature of the businesses. For years, Agilent has struggled with Keysight’s volatility and cyclicality, owing to its significant exposure to the technology and semiconductor markets (together accounting for approximately 40% of sales). The post-bubble tech recession and challenging macro-environment, coupled more recently with budget sequestration, have been overhangs for Agilent’s overall top-line growth and frustrating for life-sciences-oriented investors, who have grappled with the shares’ historically discounted valuation relative to pure-play peers. As a result, Agilent has been steadily realigning corporate resources toward important growth catalysts in the life sciences and diagnostics markets, while under-investing in and de-emphasizing its electronic measurement business.
For Agilent, the separation will allow the company to further hone its strategy and concentrate on growing organic revenue in its core businesses, which are experiencing renewed demand, based on new products, and should benefit from several industry tailwinds. For Keysight, being a standalone entity affords the same benefits. The challenge, however, will be how effectively Keysight can maintain its leadership position in a more dynamic and competitive and, importantly, maturing market. Agilent’s lack of focus on the electronic measurement business has afforded competitors incremental market share and has allowed them to more effectively invest research and development resources and leverage their balance sheets to make strategic acquisitions to position themselves for the next wave of industry growth. Somewhat paradoxically, Keysight appears to be a market leader forced to play catch-up, as the industry has shifted dramatically from the company’s legacy heritage in traditional communications testing to niche growth areas such as IP, applications performance, and security. Accordingly, Keysight must protect its intellectual property portfolio while innovating in order to maintain market share, and must quickly and meaningfully invest in emerging technologies to achieve growth targets. Whereas margins and growth opportunities seem likely to expand at post-spin Agilent, Keysight’s margins and addressable market may face more pressure owing to increased competition and customers’ budgetary constraints. Moreover, while recent results suggest that the technology markets may be stabilizing, overall visibility remains limited, and investors may continue to see volatility ahead given the book-and-ship nature of the business. While Keysight should benefit from several positive industry trends, the impact is more dependent on increased capital spending, which is likely to remain constrained until technology companies approach accelerating top-line growth. Net-net, we see a higher probability that post-spin Agilent will outgrow the industry and exceed its 6% revenue growth target than for Keysight to surpass its 3% growth target – owing to more favorable near-term sector catalysts, recent product refresh (at higher margins), improved competitive position, increased cost efficiencies, and an expanding addressable market.
For long-term investors with a tolerance for market fluctuations, Agilent shares appear to offer a compelling opportunity to gain exposure to the growing Chemical Analysis, Life Sciences and Diagnostics markets at a reasonable relative valuation. An increasingly aging global population and the requirement for standardization, more stringent testing, and tighter regulatory approvals across the biopharma, food and beverage, and agriculture industries are secular trends which suggest this is more than a product cycle story. A defensible market leadership position provides leverage for Agilent’s strategic push into high-growth emerging markets such as China and, coupled with an expanding new product pipeline, supports an argument for above-average industry growth. The potential for steadily improving margins and cash flow, geographic and end-market diversity, recurring revenues, healthy cash flow and dividend payment also offer insulation against market volatility.
Following the spin-off, Agilent shares should receive a higher multiple than those of Keysight given the company’s industry leadership position, reduced cyclicality, and better long-term growth prospects. There also appears to be potential for further appreciation, considering that improved execution should be able to drive above-market core revenue growth and earnings leverage and, in turn, narrow the valuation disparity relative to peers. Agilent’s peer group trades at 3.2x F2014 revenue projections, 22x earnings, and 14x F2014 estimated EBITDA. On a relative basis, Agilent shares appear undervalued at 19x forward earnings, a 14% discount to peers – essentially in line with their five-year historical average. The primary risk to this relative analysis, as opposed to an intrinsic assessment of valuation, is that it is essentially subjective and vulnerable to over or under-valuation stemming from sentiment shifts and other macro or sector-related volatility. Setting this risk aside, the potential for a more focused life sciences company, coupled with positive industry dynamics and improving execution, should close the relative valuation gap between post-spin Agilent and its peers. With management having reset growth targets (6% year-over-year growth, essentially in line with growth over the last three years), and offering in-line guidance and incrementally more positive commentary on end markets and new product pipeline, the stage appears set for improving performance. The potential for post-spin Agilent shares to be included in industry-specific ETFs also may expand as the life-sciences and communications-focused segments are separated.
While it is essentially impossible to reasonably forecast Agilent’s five-year earnings performance, an assumption of 10% earnings growth appears reasonable considering the company’s three-year average, at 6%. Applying this growth assumption to our F2014 EPS projection of $1.86, once can derive a five-year EPS projection of approximately $3.00/share. Assuming the current average peer P/E multiple remains intact at 22x implies a five-year share price of $66 for Agilent, versus an implied $33 today (current pre-spin price of $57.92, netting out a $25 fair value estimate for KEYS), for an annualized rate of return of 14.9%, exclusive of dividends. As a base case, one could apply a 17x earnings multiple (representing the low end of the historical comparable valuation range), and arrive at a 9.1% annualized rate of return. While Agilent has historically traded as low as 11x earnings in 2011, this was during a period of broader macroeconomic uncertainty, government and academic market weakness and underperformance in the Keysight business. It is important to note that our growth assumptions do not account for incremental earnings leverage associated with new product introductions and market share gains, a higher percentage of recurring revenues, and an increasing shift toward under-penetrated markets. Moreover, given the secular drivers for more pervasive use of Life Sciences and Diagnostics test products, and company-specific operational improvements, one could argue that management’s growth assumptions, which are in-line with historical growth, appear conservative.
Keysight comparables include broad-based and more focused electronics measurement suppliers. The group trades at approximately 12.8x F2014 EBITDA and 2.1x F2014 estimated revenue. In the near term following the spin-off, KEYS shares could experience some volatility, as a portion of the investor base might gravitate toward the stability and more focused end-market composition of the new Agilent. Moreover, while recently reported financial results appear encouraging, with a return to year-over-year growth, Keysight could again exhibit negative growth comparables, particularly as visibility remains generally very limited across the technology supply chain. Considering historical and comparable multiples on earnings, sales, and EV/EBITDA, and cash flow, Keysight can be fairly valued at $25 per share and New Agilent at about $40 per share, for a sum-of-the-parts value of $65 per share.